Upcoming conferences

Schedule a meeting with our drug development and manufacturing experts at AAPS & CPhI this November

Downloading our Case Studies

You are about to download this document, please enter your contact details below to start downloading.

Case Studies

Druggability Technologies

Druggability Technologies (DRGT) is developing DRGT-46 as a novel therapy for pain. Gabor Heltovics, CEO of DRGT, explains how Quotient Sciences enabled the rapid development, clinical assessment and commercial readiness of its DRGT- 46 product using integrated services across Quotient’s network of harmonized development and manufacturing sites in the UK and US.

Would you like to receive further scientific content including case studies, whitepapers and seminar and webinar invitations?
You can find out how we handle your personal information in our privacy policy here.

Ask us a question